Results 81 to 90 of about 7,390 (165)

B Lymphocytes in Latent Autoimmune Diabetes in Adults: From Autoimmune Activation to Immunometabolic Heterogeneity and Precision Therapeutic Perspectives

Diabetes/Metabolism Research and Reviews, Volume 42, Issue 6, September 2026.
ABSTRACT Latent autoimmune diabetes in adults (LADA) is a heterogeneous form of autoimmune diabetes characterised by adult onset, the presence of islet autoantibodies, and a slower progression to insulin dependence compared with classical type 1 diabetes.
Moncef Zouali
wiley   +1 more source

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab

, 2021
OBJECTIVE: To describe the disease course of carryover progressive multifocal leukoencephalopathy (PML) after switching from natalizumab to ocrelizumab in 2 patients with relapsing-remitting MS.
Toorop, Alyssa A, Wattjes, Mike P, Petzold, Axel, van Lierop, Zoë Y G, Killestein, Joep, Teunissen, Charlotte E, Strijbis, Eva E M, Barkhof, Frederik, van Kempen, Zoé L E, de Jong, Brigit A   +9 more
core   +1 more source

Utilization of Ocrelizumab within Different Treatment Strategies for Multiple Sclerosis: A 5-Year Population-Based Study

Neurology International
Background: We aim to provide up-to-date real-world evidence on the persistence, adherence, healthcare resource utilization, and costs of multiple sclerosis (MS) by comparing ocrelizumab to other disease-modifying treatments (DMTs) and within different ...
Marcello Moccia, Giuseppina Affinito, Giuseppina Marrazzo, Tiziana Ciarambino, Paolo Di Procolo, Licia Confalonieri, Antonio Carotenuto, Maria Petracca, Roberta Lanzillo, Maria Triassi, Vincenzo Brescia Morra, Raffaele Palladino   +11 more
doaj   +1 more source

Characterizing Combined Central and Peripheral Demyelination—Insights From a Multimodal Comparison With Chronic Inflammatory Demyelinating Polyneuropathy and Multiple Sclerosis

Muscle &Nerve, Volume 74, Issue 3, Page 605-615, September 2026.
ABSTRACT Introduction/Aims Combined central and peripheral demyelination (CCPD) is a rare dysimmune disorder sharing features with multiple sclerosis (MS) and chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Direct comparisons of central and peripheral diagnostic findings across these entities remain limited. We, therefore, performed a
N. Dubuisson, A. Kassab, P. Y. K. Van den Bergh, A. F. J. E. Vrancken, W. L. van der Pol, L. H. van den Berg, H. S. Goedee   +6 more
wiley   +1 more source

Zulassung von Ocrelizumab bringt MS-Therapie weiter voran

, 2018
Mit der EU-weiten Zulassung von Ocrelizumab (Ocrevus®) im Januar 2018 steht für Patienten mit schubförmiger Multipler Sklerose (RMS*) und früher primär progredienter Multipler Sklerose (PPMS) eine neuartige Therapie zur Verfügung, die sich selektiv gegen
Beate Grübler
core   +1 more source

The Neurovascular Niche: A Gathering Venue for Neuroinflammation and Remyelination in Multiple Sclerosis

Acta Physiologica, Volume 242, Issue 9, September 2026.
ABSTRACT In the central nervous system (CNS), the tissue microenvironment is continuously monitored and regulated to secure the unobstructed function of neurons and of their networks. This is a key function of the neurovascular niche (NVN), which is the interface between the cells of the nervous tissue and the cells and the content of blood vessels. It
Ilias Kazanis, Maria Elena Silva, Alerie G. de la Fuente, Fernando de Castro, Francisco J. Rivera   +4 more
wiley   +1 more source

Targeting progressive multiple sclerosis: Toward mechanism‐informed precision medicine

Journal of Internal Medicine, Volume 300, Issue 3, Page 238-257, September 2026.
Abstract Multiple sclerosis has undergone a therapeutic revolution over the past three decades. Randomized clinical trials and real‐world data demonstrate that modern disease‐modifying therapies substantially reduce relapse rates and acute inflammatory activity detected by magnetic resonance imaging (MRI).
Fredrik Piehl, Gonçalo Castelo‐Branco, Maja Jagodic, Tomas Olsson   +3 more
wiley   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Salpini, Romina, Aragri, Marianna, Vullo, Vincenzo, Pontecorvo, S, Iannetta, Marco, Mastroianni, Cm, Salpini, R, Iannetta, M, Svicher, V, Altieri, Marta, Zingaropoli, Ma, Annecca, R, Ciardi, Mr, Altieri, M, Aragri, M, Russo, Gianluca, Ciardi, Maria R, Russo, G, Mastroianni, Claudio M, Vullo, V, Annecca, Rosanna, Pontecorvo, Simona, Svicher, Valentina, Zingaropoli, Maria A   +23 more
core   +1 more source

OCRELIZUMAB ÎN TRATAMENTUL SCLEROZEI MULTIPLE: REVISTA LITERATURII DE SPECIALITATE

Buletinul Academiei de Ştiinţe a Moldovei: Ştiinţe Medicale
Ocrelizumab, un anticorp monoclonal umanizat care țintește celulele B CD20-pozitive, a avansat semnificativ tratamentul sclerozei multiple (SM). Aprobat atât pentru scleroza multiplă recurentă-remisivă, cât și pentru scleroza multiplă primară progresivă,
Маргарита ЕВЕРОДЖИК, Марина САНГЕЛИ, Виталий ЛИСНИК, Виктория ШИМОН, Анна БЕЛЕНЧУК   +4 more
doaj   +1 more source

Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report

Frontiers in Neurology
Drug-induced liver injury (DILI) is a potential adverse event of disease-modifying therapies (DMTs) for the treatment of multiple sclerosis (MS), as well as of methylprednisolone pulsed therapy used in case of MS relapse. DILI may be induced by different
Alice Mariottini, Alice Mariottini, Alessandro Barilaro, Antonio Lotti, Fabio Marra, Luca Massacesi, Luca Massacesi   +6 more
doaj   +1 more source